查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1521258

2024-2032 年按疾病類型（活動性結核病、潛伏性結核病等）、診斷和治療（診斷、治療）、最終用戶（醫院、專科診所、家庭護理等）和地區分類的抗結核治療市場報告

Anti-Tuberculosis Therapeutics Market Report by Disease Type (Active TB, Latent TB, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Specialty Clinics, Homecare, and Others), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球抗結核治療市場規模達14.456億美元。不斷成長的醫療保健支出、有利的報銷政策、技術進步以及不斷成長的公私合作夥伴關係是推動市場發展的一些關鍵因素。

抗結核治療是指用於控制結核病（TB）的藥物和治療策略，結核病是由結核分枝桿菌引起的細菌感染。結核病主要影響肺部，也可以擴散到身體的其他部位，例如腎臟、脊椎和大腦。抗結核治療用於消滅體內的細菌並防止感染傳播。這是透過合併使用抗生素來實現的，通常開出六到九個月的處方。一些最常用的藥物包括異煙肼、利福平、乙胺丁醇和吡嗪醯胺。所使用的藥物的確切組合取決於感染的嚴重程度和患者的健康狀況。此外，定期監測和追蹤對於確保治療成功和預防抗藥性結核病的發展也至關重要。近年來，抗結核治療受到關注，因為它還涉及支持性護理，例如氧氣治療、營養支持和可能出現的併發症的管理。

抗結核治療市場趨勢：

推動市場的主要因素之一是全球結核病（TB）的高盛行率，特別是在低收入和中等收入國家。此外，由於治療不完整、醫療基礎設施不足以及缺乏適當的醫療保健，抗藥性結核病的發生率不斷上升，這對市場成長產生了積極影響。除此之外，新藥和治療策略的發展也正在推動抗結核治療市場。近年來，貝達喹啉和德拉馬尼等多種新藥已被批准用於治療結核病。與傳統結核病藥物相比，這些藥物的療效和安全性更高。與此一致的是，技術和診斷的進步使得結核病的早期檢測和診斷成為可能，從而及時開始治療並改善患者的預後，這是另一個主要的生長誘導因素。此外，醫療保健支出的增加，特別是在新興經濟體，改善了醫療保健基礎設施，並增加了獲得優質醫療保健（包括結核病治療）的機會。除此之外，人們對結核病的認知不斷提高以及早期診斷和治療的重要性也增加了抗結核治療的需求。此外，政府對結核病控制計畫的措施和資助在推動抗結核治療市場方面發揮了重要作用。例如，政府和非政府組織 (NGO) 正在共同努力提高意識、改進診斷並確保獲得負擔得起且有效的治療，預計這將在未來幾年推動市場成長。

本報告回答的關鍵問題：

  • 迄今為止，全球抗結核治療市場表現如何，未來幾年將如何表現？
  • 全球抗結核治療市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球抗結核治療市場有何影響？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的抗結核治療市場？
  • 根據疾病類型的市場分類是怎樣的？
  • 抗結核治療市場上最具吸引力的疾病類型是什麼？
  • 基於診斷和治療的市場區隔是什麼？
  • 抗結核治療市場上最具吸引力的診斷和治療方法是什麼？
  • 基於最終用戶的市場區隔是什麼？
  • 抗結核治療市場中哪一個是最具吸引力的最終用戶？
  • 全球抗結核治療市場的競爭結構如何？
  • 全球抗結核治療市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球抗結核治療市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依疾病類型

  • 活動性結核病
    • 市場走向
    • 市場預測
  • 潛伏性結核病
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：透過診斷與治療

  • 診斷
    • 市場走向
    • 關鍵環節
      • 血液檢查
      • 影像學檢查
      • 痰液測試
      • 其他
    • 市場預測
  • 治療
    • 市場走向
    • 關鍵環節
      • 一線藥物
        • 主要類型
        • 異煙肼
        • 乙胺丁醇
        • 利福平
        • 其他
      • 二線藥物
        • 主要類型
        • 硫醋腙
        • 對氨基水楊酸 (PAS)
        • 其他
      • 其他
    • 市場預測

第 8 章：市場區隔：依最終用戶

  • 醫院
    • 市場走向
    • 市場預測
  • 專科診所
    • 市場走向
    • 市場預測
  • 居家護理
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • F. Hoffmann-La Roche Ltd.
    • Lannett Company Inc.
    • Lupin Limited
    • Macleods Pharmaceuticals Limited
    • Otsuka Pharmaceutical Co. Ltd
Product Code: SR112024A7629

The global anti-tuberculosis therapeutics market size reached US$ 1,445.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,448.5 Million by 2032, exhibiting a growth rate (CAGR) of 5.85% during 2024-2032. The rising healthcare spending, favorable reimbursement policies, technological advancements, and growing public-private partnerships represent some of the key factors driving the market.

Anti-tuberculosis therapeutics refer to the drugs and treatment strategies used to manage tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. TB primarily affects the lungs and can also spread to other parts of the body, such as the kidneys, spine, and brain. Anti-tuberculosis therapeutics are used to eradicate the bacteria from the body and prevent the spread of the infection. This is achieved through a combination of antibiotics that are typically prescribed for six to nine months. Some of the most commonly used drugs include isoniazid, rifampin, ethambutol, and pyrazinamide. The exact combination of drugs used depends on the severity of the infection and the patient's health status. In addition, regular monitoring and follow-up are also essential to ensure treatment success and prevent the development of drug-resistant TB. In recent years, anti-tuberculosis therapeutics have gained traction as it also involves supportive care, such as oxygen therapy, nutrition support, and management of complications that may arise.

Anti-Tuberculosis Therapeutics Market Trends:

One of the primary factors driving the market is the high prevalence of tuberculosis (TB) worldwide, particularly in low- and middle-income countries. Additionally, the growing incidence of drug-resistant TB due to incomplete treatment, inadequate healthcare infrastructure, and lack of access to appropriate healthcare is positively influencing the market growth. Other than this, the development of new drugs and treatment strategies is also driving the anti-tuberculosis therapeutics market. In recent years, several new drugs, such as bedaquiline and delamanid, have been approved for the treatment of TB. These drugs offer improved efficacy and safety profiles compared to traditional TB drugs. In line with this, advancements in technology and diagnostics have enabled early detection and diagnosis of TB, leading to timely initiation of treatment and better patient outcomes, which represents another major growth-inducing factor. Furthermore, the increase in healthcare spending, particularly in emerging economies, has led to improved healthcare infrastructure and increased access to quality healthcare, including TB treatment. Apart from this, the growing awareness about TB and the importance of early diagnosis and treatment has also escalated the demand for anti-tuberculosis therapeutics. Moreover, government initiatives and funding for TB control programs have played a significant role in driving the anti-tuberculosis therapeutics market. For instance, governments and non-governmental organizations (NGOs) are working together to increase awareness, improve diagnosis, and ensure access to affordable and effective treatments, which is expected to drive market growth in the upcoming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global anti-tuberculosis therapeutics market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on the disease type, diagnosis and treatment, and end user.

Disease Type Insights:

Active TB

Latent TB

Others

The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the disease type. This includes active TB, latent TB, and others.

Diagnosis and Treatment Insights:

Diagnosis

Blood Tests

Imaging Tests

Sputum Tests

Others

Treatment

First-Line of Drugs

Isoniazid

Ethambutol

Rifampin

Others

Second-Line of Drugs

Thiacetazone

Paraaminosalicyclic Acid (PAS)

Others

Others

A detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the diagnosis and treatment has also been provided in the report. This includes diagnosis (blood tests, imaging tests, sputum tests, and others), treatment (first-line of drugs (isoniazid, ethambutol, rifampin, and others) second-line of drugs (thiacetazone, paraaminosalicyclic acid (PAS), and others), and others

End User Insights:

Hospitals

Specialty Clinics

Homecare

Others

The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the end user. This includes hospitals, specialty clinics, homecare, and others.

Regional Insights:

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for anti-tuberculosis therapeutics. Some of the factors driving the North America anti-tuberculosis therapeutics market included rising prevalence of tuberculosis, growing drug resistance, and numerous government initiatives.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global anti-tuberculosis therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include F Hoffmann-La Roche Ltd., Lannett Company Inc., Lupin Limited, Macleods Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global anti-tuberculosis therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global anti-tuberculosis therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global anti-tuberculosis therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive anti-tuberculosis therapeutics market?
  • What is the breakup of the market based on the disease type?
  • Which is the most attractive disease type in the anti-tuberculosis therapeutics market?
  • What is the breakup of the market based on the diagnosis and treatment?
  • Which is the most attractive diagnosis and treatment in the anti-tuberculosis therapeutics market?
  • What is the breakup of the market based on end user?
  • Which is the most attractive end user in the anti-tuberculosis therapeutics market?
  • What is the competitive structure of the global anti-tuberculosis therapeutics market?
  • Who are the key players/companies in the global anti-tuberculosis therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anti-Tuberculosis Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease Type

  • 6.1 Active TB
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Latent TB
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Diagnosis and Treatment

  • 7.1 Diagnosis
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Blood Tests
      • 7.1.2.2 Imaging Tests
      • 7.1.2.3 Sputum Tests
      • 7.1.2.4 Others
    • 7.1.3 Market Forecast
  • 7.2 Treatment
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 First-Line of Drugs
        • 7.2.2.1.1 Major Types
        • 7.2.2.1.1.1 Isoniazid
        • 7.2.2.1.1.2 Ethambutol
        • 7.2.2.1.1.3 Rifampin
        • 7.2.2.1.1.4 Others
      • 7.2.2.2 Second-Line of Drugs
        • 7.2.2.2.1 Major Types
        • 7.2.2.2.1.1 Thiacetazone
        • 7.2.2.2.1.2 Paraaminosalicyclic Acid (PAS)
        • 7.2.2.2.1.3 Others
      • 7.2.2.3 Others
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Homecare
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 F. Hoffmann-La Roche Ltd.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 SWOT Analysis
    • 14.3.2 Lannett Company Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Lupin Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Macleods Pharmaceuticals Limited
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Otsuka Pharmaceutical Co. Ltd
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Anti-Tuberculosis Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Disease Type (in %), 2023
  • Figure 5: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Diagnosis and Treatment (in %), 2023
  • Figure 6: Global: Anti-Tuberculosis Therapeutics Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Anti-Tuberculosis Therapeutics (Active TB) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Anti-Tuberculosis Therapeutics (Active TB) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Anti-Tuberculosis Therapeutics (Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Anti-Tuberculosis Therapeutics (Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Anti-Tuberculosis Therapeutics (Homecare) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Anti-Tuberculosis Therapeutics (Homecare) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Anti-Tuberculosis Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 76: Global: Anti-Tuberculosis Therapeutics Industry: Value Chain Analysis
  • Figure 77: Global: Anti-Tuberculosis Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Anti-Tuberculosis Therapeutics Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
  • Table 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Diagnosis and Treatment (in Million US$), 2024-2032
  • Table 4: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Anti-Tuberculosis Therapeutics Market: Competitive Structure
  • Table 7: Global: Anti-Tuberculosis Therapeutics Market: Key Players